| Capsule endoscopy and double balloon: When do we really need it? | Hans Herfarth | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| MRI enterography: Is it the future of small bowel diagnostics? | Stefan Feuerbach | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| CT enterography: Is it the current sate-of-the-art for small bowel diagnostics? | Dr. David Bruining | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Session III New keys to diagnostic procedures: MRI, CT and endoscopy | Julián Panés, Edward V. Loftus | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| What about molecular predictors of prognosis and therapy: Are they the future? | Mark Silverberg | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Can serologic markers help determine prognosis and guide therapy? | Marla C. Dubinsky | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| New serologic markers for diagnosis | Iris Dotan | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Smoking, physical activity, nutrition and lifestyle: Environmental factors and their impact on IBD | Jacques Cosnes | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| New insights into IBD epidemiology –Are there any lessons for treatment? | Charles N. Bernstein | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Session II New keys to diagnostic procedures: Laboratory markers | Dermot McGovern | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| State-of-the-art lecture I | Richard S. Blumberg | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Cytokines and chemokines in IBD: What are the most interesting targets and why? | Markus F. Neurath | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| T-cell subpopulations in IBD: What do they tell us? | Warren Strober | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| New insights into IBD genetics – What have we learned and where do we go from here? | S Schreiber | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Session I Impact of new keys in pathophysiology on IBD treatment | R. Balfour Sartor, Judy Cho | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| Opening remarks | Dr. William Sandborn | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| State-of-the-art lecture II | Jürgen Schölmerich | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| What is the patient’s perspective – How important are patient reported outcomes, quality of life and disability? Nancy | Laurent Peyrin-Biroulet | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| What is “supportive therapy” – What concomitant diagnoses must be considered and treated? | David Binion | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
| What is “accelerated step up” treatment – What are the time parameters for advancing conventional therapy? | Remo Panaccione | The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology | March 26, 2010 |
How We Rank